Skip to main content

Table 2 Clinical prognostic features of CCC patients

From: Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy

Prognostic factors Cases (%) Univariate Multivariate
  96(100) Pc HR (95% CI) Pd
Age (years)   0.524   0.292
  ≤ 54 (median) 50(52.1)   1.000  
  > 54 (median) 46(47.9)   0.980(0.944–1.017)  
FIGO Stage   0.000   0.007
 Early(I + II) 64(66.7)   1.000  
 Late(III + IV) 32(33.3)   4.660(1.533–14.167)  
Residual tumor (cm)   0.115   0.541
  ≤ 1 93(96.9)   1.000  
  > 1 3(3.1)   1.690 (0.314–9.080)  
Ascites   0.005   0.338
 No 53(55.2)   1.000  
 Yes 43(44.8)   1.613(0.606–4.290)  
Endometriosis   0.121   0.568
 No 78(81.3)   1.000  
 Yes 18(18.7)   0.647(0.144–2.894)  
Chemotherapeutic response   0.000   0.003
 Platinum sensitive 64(72.7)   1.000  
 Platinum resistant 24(27.3)   7.230(1.992–26.237)  
  1. Log rank test
  2. cwithout adjustment
  3. Cox proportional hazards regression analysis
  4. dwith adjustment for age, FIGO stage, residual tumor, ascites, endometriosis, and chemotherapeutic response
  5. Bold value denotes P with statistical significance